RSHN (RushNet) Debt-to-EBITDA : 0.00 (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is RushNet Debt-to-EBITDA?

RushNet RSHN -99.00% Debt-to-EBITDA is 0.00 as of . 20.

Debt-to-EBITDA measures a company's ability to pay off its debt.

RushNet's Short-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was $0.00 Mil. RushNet's Long-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was $0.00 Mil. RushNet's annualized EBITDA for the quarter that ended in . 20 was $0.00 Mil.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for RushNet's Debt-to-EBITDA or its related term are showing as below:

RSHN's Debt-to-EBITDA is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 2.195
* Ranked among companies with meaningful Debt-to-EBITDA only.

RushNet  (OTCPK:RSHN) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

RushNet Debt-to-EBITDA Related Terms

RushNet Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for RushNet's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RushNet Debt-to-EBITDA Chart

RushNet Annual Data
Trend
Debt-to-EBITDA

RushNet Quarterly Data
Debt-to-EBITDA

RSHN vs MOJO, LBIX, KRED: Debt-to-EBITDA Comparison

For the Diagnostics & Research subindustry, RushNet's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RushNet Debt-to-EBITDA vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, RushNet's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where RushNet's Debt-to-EBITDA falls into.


RushNet Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

RushNet's Debt-to-EBITDA for the fiscal year that ended in . 20 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=( + ) / N/A
=N/A

RushNet's annualized Debt-to-EBITDA for the quarter that ended in . 20 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=( + ) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (. 20) EBITDA data.

Frequently Asked Questions Learn more about Debt-to-EBITDA →
What does a Debt-to-EBITDA of 0.00 mean?
RushNet (RSHN) has a Debt-to-EBITDA of 0.00 as of . 20. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on RushNet.
Is RushNet's Debt-to-EBITDA too high?
RushNet's current Debt-to-EBITDA is 0.00.
How does RushNet's Debt-to-EBITDA compare to MOJO and LBIX?
RushNet's Debt-to-EBITDA of 0.00 can be compared against companies in the Medical Diagnostics & Research industry. The industry median Debt-to-EBITDA is 2.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Diagnostics & Research company?
The median Debt-to-EBITDA among Medical Diagnostics & Research companies is 2.20, based on 112 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on RushNet. For the Medical Diagnostics & Research industry, the median Debt-to-EBITDA is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RushNet's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RushNet stock overvalued right now?
RushNet (RSHN) has a current Debt-to-EBITDA of 0.00. The current Debt-to-EBITDA is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For RushNet (RSHN), the current Debt-to-EBITDA is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

RushNet Business Description

Address 8465 Merchants Way, Suite 206, Orange Park, FL, USA, 32222
RushNet Inc through its subsidiary heliosDX, a National Clinical Reference Laboratory offers High-Complexity Urine Drug Testing (UDT), Behavioral Drug Testing, Allergy Droplet Cards, Oral Fluids, Infectious Disease (PCR), and NGS Genetic Testing. The firm provides physicians with individualized customer service, as well as fast and accurate reporting of results. The company invests in its infrastructure with the most efficient scientific proven instruments and the latest software for patient and physician satisfaction. It allows heliosDX to provide physicians with fast and accurate reporting meetings. The firm excels in patient and client care through physician-designed panels that aid in testing compliance and reporting education.